Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of PHAT: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders8479−5
Shares24.5M24.9M+444.6K (+1.8%)
Value$919.2M$843.6M−$75.6M (−8.2%)

New holders (12)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to PHAT in Q2 2021
InstitutionSharesValue% of portfolio
Rothschild & Co Asset Management US Inc.171,376$5.80M0.07%
Jacobs Levy Equity Management, Inc115,339$3.90M0.03%
WCM Investment Management, LLC103,987$3.52M0.01%
SEI Investments Co39,428$1.33M0.00%
Chartwell Investment Partners, LLC22,589$765.0K0.02%
PDT Partners, LLC14,900$504.0K0.03%
Russell Investments Group, Ltd.12,676$428.0K0.00%
Voya Investment Management LLC7,968$270.0K0.00%
Amundi4,513$153.0K0.00%
STRS Ohio4,100$138.0K0.00%
Leonteq Securities AG1,500$50.8K0.00%
US Bancorp17$1.00K0.00%

Sold out (17)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.